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Previous studies using L6 myotubes have suggested
that glycogen synthase kinase-3 (GSK-3) is phosphoryl-
ated and inactivated in response to insulin by protein
kinase B (PKB, also known as Akt or RAC) (Cross, D. A.
E., Alessi, D. R., Cohen, P., Andjelkovic, M., and Hem-
mings, B. A. (1995) Nature 378, 785–789). In the present
study, marked increases in the activity of PKB have
been shown to occur in insulin-treated rat epididymal
fat cells with a time course compatible with the ob-
served decrease in GSK-3 activity. Isoproterenol, acting
primarily through b3-adrenoreceptors, was found to de-
crease GSK-3 activity to a similar extent (approximately
50%) to insulin. However, unlike the effect of insulin, the
inhibition of GSK by isoproterenol was not found to be
sensitive to inhibition by the phosphatidylinositol 3*-
kinase inhibitors, wortmannin or LY 294002. The change
in GSK-3 activity brought about by isoproterenol could
not be mimicked by the addition of permeant cyclic AMP
analogues or forskolin to the cells, although at the con-
centrations used, these agents were able to stimulate
lipolysis. Isoproterenol, but again not the cyclic AMP
analogues, was found to increase the activity of PKB,
although to a lesser extent than insulin. While wortman-
nin abolished the stimulation of PKB activity by insulin,
it was without effect on the activation seen in response
to isoproterenol. The activation of PKB by isoproterenol
was not accompanied by any detectable change in the
electrophoretic mobility of the protein on SDS-poly-
acrylamide gel electrophoresis. It would therefore ap-
pear that distinct mechanisms exist for the stimulation
of PKB by insulin and isoproterenol in rat fat cells.
Glycogen synthase kinase-3 (GSK-3)1 was first discovered by
virtue of its ability to phosphorylate and inactivate the regu-
latory enzyme of glycogen synthesis in mammals, glycogen
synthase (GS) (reviewed in Refs. 1–3). In a number of tissues
GS is activated by insulin, and in skeletal muscle this has been
shown to involve the dephosphorylation of the sites phospho-
rylated by GSK-3 (4–7). This suggested that GSK-3 might be
inactivated by insulin, although more attention was initially
focused on the regulation (activation) of the relevant phospha-
tase, a glycogen-bound form of protein phosphatase-1 (PP-1G)
(8). Recently, however, it has become clear that GSK-3 itself is
indeed subject to acute regulation, being inactivated in re-
sponse to insulin or growth factors (9–16) and also following
T-cell stimulation (17). Where tested, this inactivation was
reversed by treatment with serine/threonine phosphatases in-
dicating that it was due to increased phosphorylation of GSK-3
on one or more Ser/Thr residues (11).
It has since been shown that the inactivation of GSK-3 is
associated with increased phosphorylation of a serine residue
near the N terminus (Ser-9 of the b-isoform of mammalian
GSK-3 which corresponds to Ser-21 of the a-isoenzyme) (11, 14,
16). This is of special interest since several insulin/growth
factor-activated protein kinases have been shown to phospho-
rylate these residues in GSK-3 in vitro. These include the p90
ribosomal S6 protein kinase (p90rsk), which is downstream of
the mitogen-activated protein kinase (MAP kinase) cascade,
and the p70 ribosomal S6 kinase (p70S6k) (18, 19). Studies
employing rapamycin, which selectively blocks activation of
p70S6k, appear to rule out a role for this enzyme in regulating
GSK-3 in the cell types thus far studied (10, 12, 13). The
evidence for a role for the MAP kinase pathway is mixed, with
transfection approaches (either using p90rsk itself (14) or dom-
inant negative mutants of an upstream kinase (15)) providing
evidence for a role for this pathway and recent data from fat
cells (13) and L6 myotubes (16) giving, respectively, correlative
and strong evidence against a role for the MAP kinase pathway
in regulating GSK-3 activity in response to insulin. The latter
studies (16) provided evidence that protein kinase B (PKB, also
known as RAC or Akt) might be responsible for the control of
GSK-3 in L6 myotubes. PKB phosphorylates Ser-9 and Ser-21
in the b- and a-isoforms of GSK-3, respectively, is activated by
insulin (16, 20, 21), and may lie downstream of phosphatidyli-
nositol 39-kinase (PI 39-kinase) (16, 22). PI 39-kinase is impli-
cated in the control of GSK-3 in several cell types by the
observation that wortmannin, a selective but not absolutely
specific inhibitor of PI 39-kinase, blocks the inactivation of
GSK-3 by insulin and other agents (10, 12, 13, 16). LY 294002,
a structurally unrelated inhibitor of PI 39-kinase (23), has
recently been shown to block the insulin-induced inactivation
of GSK-3 in L6 myotubes (16).
In this study we demonstrate that insulin activates PKB in
rat fat cells and that this may underlie the effects of insulin on
GSK-3 activity in these cells. In addition, we report that the
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b-adrenergic agonist, isoproterenol, also causes the stimulation
of PKB and inactivation of GSK-3 in fat cells. The effects of
isoproterenol on these two kinases do not appear to be medi-
ated by increases in the intracellular level of cAMP. A number
of lines of evidence suggest that distinct mechanisms are in-
volved in the activation of PKB by insulin and isoproterenol.
EXPERIMENTAL PROCEDURES
Materials—Male Wistar rats were fed ad libitum up to the time of
killing on a stock laboratory diet (CRM; Bioshore, Manea, Cambs, UK).
Collagenase was purchased from Worthington Diagnostic Systems
(Freehold, NJ). Enhanced chemiluminescence Western blotting detec-
tion kits and [g-32P]ATP were from Amersham Int. (Amersham, Bucks,
UK), and pepstatin, leupeptin, and antipain were from Cambridge
Research Biochemicals (Harston, Cambs, UK). Microcystin, dithiothre-
itol, and rapamycin were obtained from Calbiochem (Nottingham, UK).
LY 294002 was purchased from the Alexis Corp. (Nottingham, UK). All
other chemicals and biochemicals were from Sigma or BDH (both of
Poole, Dorset, UK). The b3-agonist, BRL 37344, was a gift from Dr. P.
Young of SmithKline Beecham Pharmaceuticals (Welwyn, Herts, UK).
The PKB antiserum was raised in rabbits immunized with a synthetic
peptide corresponding to residues 465–480 of the human PKB sequence
and was used without further purification. Anti-GSK-3 serum was a gift
from Dr. J. Vandenheede (Katholieke Universiteit, Leuven, Belgium).
All synthetic peptides, including those used for the assay of GSK-3,
p70S6k, and PKB were synthesized by Dr. G. Bloomberg (Dept. of Bio-
chemistry, University of Bristol, UK). Wortmannin and rapamycin
were dissolved in dimethyl sulfoxide and stored at 220 °C.
Preparation and Incubation of Epididymal Fat Cells—Adipocytes
were isolated from epididymal fat pads, preincubated, and then incu-
bated (at 150–250 mg cell dry weight/ml) as described previously (13,
24). For fat cells treated with wortmannin, LY 294002, or rapamycin,
the appropriate control incubations contained 0.1% dimethyl sulfoxide.
Assays of GSK-3, p70S6k, and PKB—The activities of GSK-3 and
p70S6k were measured in immunoprecipitates using peptide substrates
as described previously (13). For the measurement of PKB activity,
adipocytes (150–200 mg dry cell weight) were extracted in 1 ml of 50
mM Hepes (pH 7.6), 0.2 mM EDTA, 2.2 mM EGTA, 1 mM dithiothreitol,
100 mM KCl, 10% glycerol, 1% Triton X-100, 1 mM microcystin, and 1
mg/ml each of pepstatin, leupeptin, and antipain. PKB was then immu-
noprecipitated from 750 ml of cell extracts with 5 mg of protein A-
Sepharose and 5 ml of PKB antiserum for 2 h at 4 °C. Immunoprecipi-
tates were washed twice with 1 ml of PKB assay buffer (20 mM MOPS
(pH 7.0), 1 mM EDTA, 1 mM EGTA, 0.01% Brij 35, 5% glycerol) contain-
ing 0.5 M NaCl and twice with 1 ml of the same buffer without added
salt. The protein A beads were finally resuspended in 40 ml of PKB
assay buffer containing 0.1% mercaptoethanol and 2.5 mM cAMP-de-
pendent protein kinase inhibitor peptide (IP20). The activity of PKB in
these immunoprecipitates was measured using either myelin basic
protein (MBP, 0.5 mg/ml final concentration) or the synthetic peptide
based on the sequence surrounding the serine phosphorylation site of
GSK-3 (Ser-21 of GSK-3a and Ser-9 of GSK-3b), “cross-tide” (16) (100
mM), for 15 min at 30 °C.
Anion Exchange Chromatography, Gel Electrophoresis, and Immu-
noblotting of PKB—To separate proteins by anion exchange chromatog-
raphy, fat cells were extracted as above and applied to a Pharmacia
SMART system Mono Q column equilibrated with Buffer A (50 mM Tris
(pH 7.3), 2 mM EDTA, 2 mM EGTA, 5% glycerol, 0.03% Brij 35 (w/v),
0.1% mercaptoethanol, and 1 mg/ml pepstatin, leupeptin, and antipain).
The column was developed with a 0–50% gradient of Buffer B (Buffer A
plus 1 M NaCl) at a flow rate of 50 ml/min. Fractions (100 ml) were
assayed for cross-tide kinase activity (10-ml fraction in a final reaction
volume of 25 ml).
Western blotting was performed using immunoprecipitates run on
16-cm SDS-10% polyacrylamide gels (25) and blotted onto Immobilon-P
FIG. 1. Time course for the effect of insulin and isoproterenol
of GSK-3. Adipocytes were incubated with insulin (83 nM, E) or isopro-
terenol (1 mM, l) for the times indicated prior to extraction. Results are
expressed as a percentage of the control value at time 0 (39.5 6 4.9 pmol
of phosphate incorporated into substrate peptide/min/g dry cells, n 5 3)
and are means 6 S.E. for three separate cell preparations. In the
absence of hormones the activity of GSK-3 did not alter significantly
with time and was 39.3 6 3.2 pmol of phosphate/min/g dry cells (n 5 3)
after the 40-min incubation.
FIG. 2. The effect of b-adrenergic agonists and agents that
increase intracellular cAMP levels on GSK-3 activity. A, adipo-
cytes were incubated for 10 min with 83 nM insulin (Ins), 1 mM isopro-
terenol (Iso), 5 nM BRL37344 (BRL), 2 mM cpt-cAMP (cpt), 5 mM db-
cAMP (db), or 5 nM forskolin (For) prior to extraction. Where indicated
10 mM propranolol (Pro) was added 10 min before addition of isoproter-
enol. Results are expressed as a percentage of the control value (no
additions) for GSK-3 activity (45.6 6 3.0 pmol of phosphate incorpo-
rated into substrate peptide/min/g dry cells, n 5 nine separate cell
preparations) and are means 6 S.E. for the number of separate cell
preparations shown in parentheses. Significance, as assessed by the
Student’s t test, is indicated as follows: **, p , 0.0001, *, p , 0.001
versus appropriate control. B, dose response for the effect of BRL37344
on GSK-3 activity. Adipocytes were incubated for 10 min with varying
concentrations of BRL 37344. Results are expressed as a percentage of
the control value in the absence of BRL37344 (see A) and are means 6
S.E. for two separate cell preparations.
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membrane (Millipore, Watford, Herts, UK). Blots were incubated with
PKB antiserum at a 1:400 dilution and immunoreacting proteins were
visualized using the enhanced chemiluminescence detection system.
Assays of Glycogen Synthase and Lipolysis—The activity of glycogen
synthase in fat cell extracts was determined as described elsewhere
(13). Lipolysis was assayed by measuring the appearance of glycerol in
the incubation medium (26).
RESULTS
Inactivation of GSK-3 in Fat Cells in Response to Isoproter-
enol—Incubation of adipocytes with isoproterenol led to a rapid
decrease in the activity of GSK-3 (Fig. 1). Maximum inactiva-
tion of GSK-3 in response to isoproterenol was seen after ap-
proximately 20 min and was sustained for at least 40 min. This
time course and the extent of inactivation (approximately 50%)
were broadly similar to the changes in GSK-3 activity seen in
response to insulin (see Fig. 1 and Ref. 13), although the effect
of insulin was more rapid in onset. The effects of insulin and
isoproterenol on GSK-3 activity were not additive (Fig. 2A).
GSK-3 activity in all experiments was measured by following
phosphate incorporation into a peptide substrate correspond-
ing to the GSK-3 phosphorylation site in eukaryotic initiation
factor-2B.2 A similar inactivation of GSK-3 in response to iso-
proterenol was also observed when the kinase was assayed
using a peptide based on its phosphorylation site in GS (see
Ref. 13) (data not shown).
In order to investigate the mechanism by which isoprotere-
nol inactivates GSK-3 in fat cells, a number of agents designed
to either mimic or inhibit the effects of b-adrenergic agents was
tested. The effects of isoproterenol on fat cells are mediated
through its actions on b-adrenergic receptors. However, the
effects of isoproterenol on GSK-3 in this system were not
blocked by the classical b1-/b2-antagonist propranolol (Fig. 2A).
This finding suggested that isoproterenol may be acting pri-
marily via the b3-receptor which is known to be insensitive to
propranolol (see Ref. 28). The b3-receptor is thought to be the
primary adrenergic receptor mediating the effects of b-adrener-
gic agents on lipolysis in rat white adipose tissue (29). Like
isoproterenol, the b3-receptor-specific agonist, BRL 37344 (30,
31), caused a significant decrease in the activity of GSK-3 (Fig.
2A). The effects of BRL 37344 on GSK-3 activity were half-
maximal at approximately 5 nM (Fig. 2B). This is consistent
with reported EC50 values for the actions of BRL 37344 on the
stimulation of lipolysis in this cell type (32–34).
The binding of b-adrenergic agonists to their receptors acti-
vates adenylate cyclase and thereby increases cytoplasmic
cAMP levels. In order to address the possibility that the inac-
tivation of GSK-3 was a consequence of elevated cAMP, we
adopted two approaches. In the first, cells were treated with
the cell-permeant cAMP analogues, db-cAMP and cpt-cAMP.
This had no effect on the activity of GSK-3 (Fig. 2A) although
they did stimulate lipolysis over 8-fold (see Table I). In the
second, we made use of forskolin, which activates adenylate
cyclase. Treatment of cells with forskolin also failed to cause
inactivation of GSK-3 (Fig. 2A) but did increase the rate of
lipolysis in these cells to an extent comparable with isoproter-
enol (Table I). It therefore seems unlikely that isoproterenol
acts via cAMP to inactivate GSK-3 in these cells. Table I also
shows the effects of various agents on the activity ratio ((2/1)-
glucose 6-phosphate) of GS in fat cells. Despite decreasing the
activity GSK-3, neither isoproterenol nor BRL 37344 on their
own had any effect on the activity ratio of GS. The pronounced
stimulation of GS seen with insulin was approximately halved
when isoproterenol was included in the incubation.
The Isoproterenol-induced Inactivation of GSK-3 Is Not
Blocked by Inhibitors of PI 39-Kinase or by Rapamycin—Since
the inactivation of GSK-3 by isoproterenol could not be mim-
icked by raising intracellular cAMP levels, we sought to exam-
ine other possible mechanisms by which this effect might occur.
In rat fat cells, the inactivation of GSK-3 by insulin is blocked
by wortmannin, an inhibitor of PI 39-kinase (13). In contrast,
wortmannin had no effect on the inactivation of GSK-3 by
isoproterenol or by BRL 37344. (Fig. 3). Since wortmannin does
block the regulation of GSK-3 by other stimuli such as epider-
mal growth factor and insulin-like growth factor-1 in other cell
types (10, 12, 16), the mechanism by which adrenergic agonists
decrease GSK-3 activity appears to be quite distinct from that
employed by agents acting through receptor tyrosine kinases.
To further test for the possible involvement of PI 39-kinase in
the effect of isoproterenol on GSK-3, the fat cells were pre-
treated with the unrelated PI 39-kinase inhibitor LY 294002.
As is the case for wortmannin, although LY 294002 abolished
the effect of insulin on GSK-3, it was unable to prevent the
inhibition seen in response to isoproterenol (Fig. 3).
As the inactivation of GSK-3 induced by isoproterenol was
not affected by wortmannin, which completely blocks activation
of p70S6k by insulin in fat cells (13), it is very unlikely that the
inactivation of GSK-3 is mediated by this signaling pathway.
This is supported by the observation that rapamycin (which
specifically blocks the activation of p70S6k without affecting
MAP kinase) had no effect upon the inactivation of GSK-3
induced by isoproterenol or BRL 37344 (Fig. 3). Rapamycin also
has no effect upon the control of GSK-3 in other cell types
tested (10, 12, 13, 16). At the dose used here (20 nM), rapamycin
completely blocked the activation of p70S6k induced by insulin
(see Ref. 13).
Insulin and Isoproterenol Activate PKB in Rat Epididymal
Fat Cells—Cross et al. (16) have recently shown that PKB can
phosphorylate GSK-3 in vitro and cause its inactivation. PKB
phosphorylates the same N-terminal serine residue phospho-
rylated by p70S6k or p90rsk (18, 19). Since PKB is thought to be2 G. I. Welsh, J. C. Patel, and C. G. Proud, submitted for publication.
TABLE I
The effect of various agents on lipolysis and glycogen synthase activity ratio
Adipocytes were incubated with effectors as shown for 10 min prior to extraction. Extracts were assayed for GS activity in the presence or absence
of glucose 6-phosphate, while the cell incubation media were retained for glycerol assays. Results are shown as the average measurement
determined from the number of separate cell preparations shown in parentheses. Where appropriate (for n . 2), values are 6 S.E., and significance
(p , 0.01 versus control) is assessed by Student’s t test and is denoted by *.
Condition Rate of lipolysis (nmol glycerolreleased/10 min/g dry cells) GS activity ratio ((2/1)-glucose 6-phosphate)
Control 207 6 39 (6) 0.048 6 0.009 (6)
Insulin (83 nM) 225 6 47 (6) 0.238 6 0.048 (6)*
Isoproterenol (1 mM) 2495 6 340 (6)* 0.059 6 0.008 (6)
Insulin 1 isoproterenol 2833 (2) 0.113 (2)
BRL37344 (5 nM) 1393 (2) 0.030 (2)
cpt-cAMP (2 mM) 1648 (2) 0.063 (2)
db-cAMPa (5 mM) 2512 (2) 0.055 (2)
Forskolin (5 nM) 2425 (2) 0.057 (2)
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downstream of PI 39-kinase (20, 22), this would provide an
explanation of the ability of wortmannin to block completely
the regulation of GSK-3 by insulin and other stimuli. Thus,
insulin by, for example, activating PI 39-kinase would also
bring about the activation of PKB and therefore the phospho-
rylation and inactivation of GSK-3.
We have therefore examined the regulation of PKB activity
by insulin and isoproterenol in fat cells. Extracts from adipo-
cytes treated with insulin or isoproterenol were separated by
Mono Q chromatography essentially as described by Cross et al.
(16). Insulin increased the kinase activity toward cross-tide in
two broad peaks (I and II) (Fig. 4). Peak I (eluting between
150–250 mM NaCl) was found to coincide with the elution
position of PKB as shown by immunoblotting (Fig. 4, inset). The
cross-tide kinase activity eluting at this position was thus due,
at least in part, to the activity of PKB. Immunoreactive PKB
could not be detected in peak II, and thus the activity toward
cross-tide in these fractions is likely to be due to some other
unidentified kinase. Isoproterenol increased the kinase activity
toward cross-tide in peak I but not peak II. The effect of iso-
proterenol on the kinase activity in this peak was less than the
stimulation seen in response to insulin.
The stimulation of PKB by both insulin and isoproterenol in
whole cell extracts was confirmed by measuring kinase activity
in anti-PKB immunoprecipitates using either cross-tide or my-
elin basic protein as a substrate. Table II shows that the both
hormones increase the activity of PKB, with the effects of
insulin being greater than those of isoproterenol. The fold
effects observed were similar whether cross-tide or MBP was
used to measure kinase activity. To further verify that the
kinase activity measured in immunoprecipitates was actually
PKB, we preincubated the protein A-Sepharose beads with
anti-PKB antibody plus the peptide to which the antiserum
was raised (see “Experimental Procedures”) prior to the addi-
tion of beads to fat cell extracts. This peptide was able to
compete with PKB for binding to the antiserum, as shown by
its ability to abolish kinase activity toward MBP in immuno-
precipitates from control, insulin-, or isoproterenol-treated cell
extracts (data not shown).
The time courses for activation of PKB by insulin and iso-
proterenol are shown in Fig. 5. Insulin caused an extremely
rapid stimulation of PKB activity which declined slowly over 40
min. In contrast, the activation in response to isoproterenol
was slower and more transient. A comparison of the time
courses for GSK-3 inactivation (Fig. 1) and PKB stimulation
(Fig. 5) shows a number of discrepancies between the two.
First, complete activation of PKB, even with isoproterenol, was
seen after 5 min, while maximal inhibition of GSK-3 occurred
only after 20 min. Second, inactivation of GSK-3 was sustained
even after PKB activities had returned to basal levels.
The stimulation of PKB by insulin has also been reported in
a number of other cell types (16, 20, 21) and is accompanied by
a change in the mobility of the protein on SDS-PAGE. This
band-shift in response to insulin is thought to be a result of
changes in the phosphorylation of PKB (21, 22, 35) and may be
seen on stimulation of fat cells with the hormone (see Fig. 6
inset and Ref. 21). Interestingly the increase in PKB activity on
treatment with isoproterenol is not associated with any detect-
able change in the electrophoretic mobility of the protein. The
effects of insulin and isoproterenol on PKB activity were not
additive (Fig. 6). The primary effect of isoproterenol again
appears to be via the b3-adrenergic receptor because BRL
37344 is also able to stimulate PKB. The lack of effect of either
cpt-cAMP or db-cAMP indicates that the increase of PKB ac-
tivity in response to b-adrenergic agonists does not occur as a
result of increased cytoplasmic cAMP levels (Fig. 6).
The data in Fig. 7 show that while the effect of insulin was
FIG. 3. The effects of wortmannin, LY 294002, and rapamycin
on the stimulation of GSK-3 activity by insulin and b-adrenergic
agonists. Adipocytes were pretreated with wortmannin (100 nM) or
rapamycin (20 nM) for 30 min or with LY 294002 (50 mM) for 15 min
prior to the addition of hormones for a further 10 min. Abbreviations for
the effectors are as outlined in Fig. 2A. Results are expressed as a
percentage of the control value (see Fig. 2A) and are means 6 S.E. for
the number of separate cell preparations shown in parentheses. Where
appropriate significance (assessed as in Fig. 2A) is indicated as follows:
**, p , 0.001; *, p , 0.05.
FIG. 4. Identification of PKB by Mono Q chromatography. Ex-
tracts were prepared from fat cells treated with insulin (l), isoproter-
enol (), or no additions (E) and fractionated by Mono Q chromatogra-
phy. PKB activity is expressed as pmol of phosphate incorporated into
cross-tide/min/ml fraction. The salt gradient is indicated by the dotted
line. Similar results were obtained with four separate cell preparations.
Inset, Western blot showing elution position of PKB from insulin-
treated extracts. PKB was not detected in any other fractions. The
elution position of PKB did not change under control or isoproterenol-
treated conditions.
TABLE II
Measurement of PKB activity using myelin basic protein or cross-tide
Adipocytes were incubated with insulin (83 nM) or isoproterenol (1
mM) for 10 min prior to extraction. The MBP or cross-tide kinase activity
was measured in anti-PKB immunoprecipitates as described under
“Experimental Procedures.” Results are expressed as pmol of 32P incor-
porated into substrate/min/g dry 6 S.E. for the number of separate cell
preparations shown in parentheses. Significance of the hormone effects
(versus control) is assessed by the Student’s t test, and is denoted by *
(p , 0.001).
Condition MBP kinase activity Cross-tide kinaseactivity
Control 0.56 6 0.04 (10) 0.46 6 0.03 (3)
Insulin 1.85 6 0.13 (17)* 2.20 6 0.32 (3)*
Isoproterenol 1.15 6 0.05 (15)* 1.24 6 0.13 (3)*
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abolished by preincubation of the adipocytes with wortmannin,
the inhibitor had no significant effect on the stimulation of
PKB by isoproterenol. In agreement with others (21), wortman-
nin also reversed the effect of insulin on the band-shift seen
with PKB on SDS-PAGE (data not shown). Rapamycin was
without effect on changes in the activity of PKB in response to
either hormone (data not shown).
Given that PKB is reported to lie upstream of p70S6k (22), we
determined whether isoproterenol activated this kinase. Iso-
proterenol gave a significant activation, which was blocked by
rapamycin but was modest in comparison to that induced by
insulin (Fig. 8). In contrast to the effect of isoproterenol on PKB
activation and GSK-3 inhibition, the increase in p70S6k activity
was largely eliminated by wortmannin and rapamycin.
DISCUSSION
GSK-3 in Rat Epididymal Fat Cells Is Activated by Isopro-
terenol as Well as Insulin—The data presented in this paper
show that in freshly isolated rat adipocytes treated with iso-
proterenol, there is a marked inhibition of GSK-3 activity.
Isoproterenol was also found to increase the activity of the
kinase proposed to be upstream of GSK-3, namely PKB. We
have been unable to find any change in the activity ratio of GS
FIG. 6. The effect of insulin, b-adrenergic agonists, and cAMP
analogues on PKB activity. Adipocytes were incubated with 83 nM
insulin (Ins), 1 mM isoproterenol (Iso), 5 nM BRL 37344 (BRL), 2 mM
cpt-cAMP (cpt), or 5 mM db-cAMP (db) for 10 min prior to extraction.
Results are expressed as a percentage of the control value (no additions)
for PKB activity (0.56 6 0.04 pmol of phosphate incorporated into
MBP/min/g dry cells, n 5 10 separate cell preparations) and are
means 6 S.E. for the number of separate cell preparations shown in
parentheses. Where appropriate significance (assessed as in Fig. 2A) is
indicated as follows: **, p , 0.001; *, p , 0.05. Inset shows a Western
blot of anti-PKB immunoprecipitates from control (Con), insulin (Ins),
or isoproterenol (Iso)-treated fat cell extracts. IgG indicates the position
of the immunoglobulin heavy chains.
FIG. 8. Effect of isoproterenol on p70S6k activity. Adipocytes
were preincubated with wortmannin (100 nM) or rapamycin (20 nM) for
30 min as indicated prior to the addition of insulin (Ins) or isoproterenol
(Iso). Results are expressed as a percentage of the control (Con) value
(4.0 6 0.5 pmol of phosphate incorporated into substrate peptide/min/g
dry cells, n 5 9) and are means 6 S.E. for the number of separate cell
preparations shown in parentheses. Where appropriate significance (as-
sessed as in Fig. 2A) is indicated as follows: **, p , 0.001; *, p , 0.05.
FIG. 5. Time course for activation of PKB by insulin and iso-
proterenol. Adipocytes were incubated with insulin (E) or isoprotere-
nol (l) for the times indicated. The results are expressed as percentage
increase from the control PKB activity at time 0 (0.53 6 0.11 pmol of
phosphate incorporated into MBP/min/g dry cells, n 5 3 separate cell
preparations) and are the average 6 S.E. from three separate cell
preparations. PKB activity in the absence of hormones did not alter
significantly over the incubation period and was 0.49 6 0.05 pmol of
phosphate/min/g dry cells (n 5 3) at 40 min.
FIG. 7. The effect of wortmannin on the activation of PKB by
insulin and isoproterenol. Adipocytes were preincubated with wort-
mannin (100 nM) for 30 min. Cells were then incubated for a further 10
min with no further additions (Con), 83 nM insulin (Ins), or 1 mM
isoproterenol (Iso). Results are expressed as a percentage of the control
value for PKB activity (see Fig. 6) and are means 6 S.E. for the number
of separate cell preparations shown in parentheses. Where appropriate
significance (assessed as in Fig. 2A) is indicated as follows: **, p ,
0.001; *, p , 0.05. DMSO, dimethyl sulfoxide.
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((2/1)-glucose 6-phosphate) in response to isoproterenol; in-
deed, isoproterenol partially reverses the activation of GS seen
in response to insulin (see also Ref. 36). Since decreases in
GSK-3 activity have been proposed to be responsible, at least in
part, for activation of GS, these findings were of interest. Our
results seem to indicate that GSK-3 is not the primary regula-
tor of GS activity in rat fat cells and suggest that PP1-G
probably plays a more important role in the regulation of gly-
cogen synthesis in vivo. It has been suggested that PP1-G plays
the dominant role in the regulation of rat muscle GS (see Ref.
37). The mechanisms involved in the regulation of glycogen
metabolism in different tissues may be distinct. In rat muscle
(37) and in 3T3-L1 adipocytes (38) the stimulation of GS by
insulin is partially sensitive to inhibition by rapamycin,
whereas in primary rat adipocytes it is not (13).
PKB in Rat Epididymal Fat Cells Is Activated by Insulin and
Isoproterenol by Apparently Different Mechanisms—As PKB
has been implicated as the direct upstream regulator of GSK-3
in L6 myotubes (16), it was important to determine its activity
in adipocytes. Here we report the first direct measurement of
PKB activity in rat fat cells and have shown substantial and
rapid stimulation of the kinase in response to insulin. Isopro-
terenol was also found to activate PKB in these cells. Overall,
the congruence between the actions of all effectors on GSK-3
inactivation and PKB activation supports the view that PKB is
the upstream regulator of GSK-3 in fat cells, as concluded by
Cross et al. (16) from their studies in L6 myotubes. In further
agreement with this view, the activation of PKB in the present
study is considerably more rapid than the inactivation of
GSK-3 (Figs. 1 and 5). However, in the absence of a specific
inhibitor of PKB it is not possible to obtain conclusive proof
that PKB is indeed upstream of GSK-3.
The finding that isoproterenol also causes a small stimula-
tion of p70S6k is interesting in light of the proposal that this
kinase is downstream of PKB (22). The physiological relevance
for the activation of this S6 kinase under these conditions
remains to be explained.
Our results also have important implications for understand-
ing the mechanisms by which PKB is regulated in fat cells. The
exact means by which PKB activity is controlled remains ob-
scure, with a number of different factors being implicated,
acting either independently or in conjunction with each other.
In other cell types there is strong evidence that the activation
of PKB is mediated via PI 39-kinase (20, 22), although the
direct involvement of PI 39-kinase products remains controver-
sial (20, 39). In fat cells, the differing effects of wortmannin on
PKB activation by insulin and isoproterenol, along with the
failure of isoproterenol to produce a band-shift in PKB, would
seem to indicate that different mechanisms are involved in the
stimulation of the kinase by these hormones. A role for PI
39-kinase in the activation of PKB by insulin in fat cells seems
likely as the stimulation is abolished by preincubation with
wortmannin. Changes in PKB activity in response to isopro-
terenol do not appear to involve PI 39-kinase activation as this
inhibitor was without effect. Isoproterenol has no effect on
adipocyte PI 39-kinase activity when measured in anti-PI 39-
kinase p85 immunoprecipitates (40). It is, however, possible
that b-adrenergic agonists increase the amount of PI 39-kinase
products in fat cells via activation of another, as yet uncharac-
terized, isoform of PI 39-kinase. Indeed, a Gbg-sensitive isoform
of PI 39-kinase has been described in myeloid-derived cells and
in platelets (41, 42).
In agreement with Kohn et al. (21), the activation of PKB in
fat cells in response to insulin was accompanied by a change in
the mobility of the kinase on SDS-PAGE. In this respect, the
mechanism by which isoproterenol activates PKB again clearly
differs from that involved in insulin action, as it is not associ-
ated with a change in the migration of the protein on gel
electrophoresis (Fig. 6, inset). The activation of the kinase and
SDS-PAGE band-shift in response to platelet-derived growth
factor in Rat-1 fibroblasts is thought to be a direct result of
changes in the phosphorylation of PKB, as both are reversed by
treatment with phosphatase (22). It is likely that activation of
PKB by insulin in fat cells involves a similar phosphorylation
step. Activation in response to isoproterenol, however, appears
to occur independently of the phosphorylation event responsi-
ble for band-shift of the protein. It is possible that isoproterenol
induces changes in the phosphorylation of PKB which cause
changes in kinase activity but are not manifested as changes in
its electrophoretic mobility.
Finally, it has been proposed that activation of PKB can
occur as a result of protein-protein interactions mediated by its
pleckstrin homology domain (43, 44). The pleckstrin homology
domains from the three known PKB isoforms (a, b, and g) have
recently been shown to interact with PKC-a, -d, and -z subtypes
and with G protein bg subunits (Gbg) in vitro (43), but the
effects of these interactions on PKB activity have yet to be
determined. It is possible that the effect of isoproterenol is
mediated by the binding of Gbg subunits to the pleckstrin
homology domain, in a manner analogous to the activation of
b-adrenergic receptor kinase on binding of Gbg (see Ref. 27).
Further work clearly needs to be done to clarify the question of
how b-adrenergic agonists stimulate PKB.
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